Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 1, 2008, Pages 19-31

  Werner, Sebastian ^a   Mendoza, Arnulfo ^b   Hilger, Ralf A ^c   Erlacher, Miriam ^a   Reichardt, Wilfried ^a   Lissat, Andrej ^a   Konanz, Claudia ^a   Uhl, Marcus ^a   Niemeyer, Charlotte M ^a   Khanna, Chand ^b   Kontny, Udo ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Apoptosis; Busulfan; Chemosensitivity; Ewing's sarcoma; Mouse; Pharmacokinetics; Treosulfan; Xenograft

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ALKYLATING AGENT; BUSULFAN; CASPASE 3; CASPASE 9; DNA FRAGMENT; LIPOCORTIN 5; TREOSULFAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; EWING SARCOMA; FEMALE; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANNEXIN A5; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BISBENZIMIDE; BLOTTING, WESTERN; BUSULFAN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COLORING AGENTS; G1 PHASE; INDICATORS AND REAGENTS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, NUDE; SARCOMA, EWING'S; TETRAZOLIUM SALTS; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42149182446     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0566-9     Document Type: Article

References (46)

1. Khoury JD (2005) Ewing sarcoma family of tumors. Adv Anat Pathol 12:212-220
2. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359:162-165
3. Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, Amann G, Dockhorn-Dworniczak B, Harms D, Muller-Weihrich S, Welte K, Kornhuber B, Janka-Schaub G, Gobel U, Treuner J, Voute PA, Zoubek A, Gadner H, Jurgens H (2001) Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 19:1818-1829
4. Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, Craft AW (2000) Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 18:3108-3114
5. Rodriguez-Galindo C, Billups CA, Kun LE, Rao BN, Pratt CB, Merchant TE, Santana VM, Pappo AS (2002) Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer 94:561-569
6. Frohlich B, Ahrens S, Burdach S, Klingebiel T, Ladenstein R, Paulussen M, Zoubek A, Jurgens H (1999) High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS. Klin Padiatr 211:284-290
7. Ladenstein R, Lasset C, Pinkerton R, Zucker JM, Peters C, Burdach S, Pardo N, Dallorso S, Coze C (1995) Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 15:697-705
8. Hassan M (1999) The role of busulfan in bone marrow transplantation. Med Oncol 16:166-176
9. van der Jagt RH, Appelbaum FR, Petersen FB, Bigelow CL, Fisher LD, Schoch GH, Buckner CD, Sanders JE, Storb R, Sullivan KM (1991) Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. Bone Marrow Transplant 8:211-215
10. Gropp M, Meier W, Hepp H (1998) Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol 71:94-98
11. Hartley JA, O'Hare CC, Baumgart J (1999) DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer 79:264-266
12. Koenigsmann M, Mohren M, Jentsch-Ullrich K, Franke A, Becker E, Heim M, Freund M, Casper J (2004) High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone Marrow Transplant 34:477-483
13. Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME, Basara N, Fauser AA, Hertenstein B, Mylius HA, Baumgart J, Pichlmeier U, Hahn JR, Holler E (2005) Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 35:233-241
14. Bitan M, Shapira MY, Resnick IB, Zilberman I, Miron S, Samuel S, Ackerstein A, Elad S, Israel S, Amar A, Fibach E, Or R, Slavin S (2005) Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells. Exp Hematol 33:713-718
15. Casper J, Wilhelm S, Steiner B, Wolff D, Grobe N, Hahling D, Hartung G, Hilgendorf I, Luck A, Junghanss C, Kahl C, Baumgart J, Pichlmeier U, Freund M (2005) Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine. Dtsch Med Wochenschr 130:2125-2129
16. Kroger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A (2006) Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 37:339-344
17. Fruehauf S, Buss EC, Tropaly J, Kreipe HH, Ho AD (2005) Myeloablative conditioning in myelofibrosis using i.v. treosulfan and autologous peripheral blood progenitor cell transplantation with high doses of CD34+ cells results in hematologic responses. A follow-up of three patients. Haematologica 90:ECR08
18. Markiewicz M, Wojciechowska M, Wylezol I, Wozniczka K, Giebel S, Wojnar J, Krawczyk-Kulis M, Mendek-Czajkowska E, Holowiecki J (2006) Unrelated donor bone marrow transplantation with treosulfan-based myeloablative conditioning for paroxysmal nocturnal hemoglobinuria-successful treatment despite multiple transplant-related risk factors for hemolysis including major Kidd group incompatibility. Bone Marrow Transplant 37:231-232
19. Wachowiak J, Chybicka A, Kowalczyk J, Boruczkowski D, Gorczynska E, Wojcik B, Leda M, Drabko K, Pieczonka A, Turkiewicz D, Kawak K, Choma M (2005) Retrospective study on treosulfan-based preparative regimen for allogeneic HSCT in children with hematological malignancies and high risk of conventional regimen related toxicity. Bone Marrow Transplant 35(S2):261 (Abstract)
20. Drabko K, Zawitkowska-Klaczynska J, Wojcik B, Choma M, Zaucha-Prazmo A, Kowalczyk J, Gorczynska E, Toporski J, Kalwak K, Turkiewicz D, Chybicka A (2005) Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma. Pediatr Transplant 9:618-621
21. Lanvers-Kaminsky C, Bremer A, Dirksen U, Jurgens H, Boos J (2006) Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines. Anticancer Drugs 17:657-662
22. Dirksen U (2007) Treosulfan high dose therapy with autologous stem cell rescue in high-risk Ewing tumors. J Clin Oncol 25(18S):100039 (Abstract)
23. Kontny HU, Lehrnbecher TM, Chanock SJ, Mackall CL (1998) Simultaneous expression of Fas and nonfunctional Fas ligand in Ewing's sarcoma. Cancer Res 58:5842-5849
24. Kontny HU, Hammerle K, Klein R, Shayan P, Mackall CL, Niemeyer CM (2001) Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis. Cell Death Differ 8:506-514
25. Meric F, Liao Y, Lee WP, Pollock RE, Hung MC (2000) Adenovirus 5 early region 1A does not induce expression of the ewing sarcoma fusion product EWS-FLI1 in breast and ovarian cancer cell lines. Clin Cancer Res 6:3832-3836
26. Merino ME, Navid F, Christensen BL, Toretsky JA, Helman LJ, Cheung NK, Mackall CL (2001) Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction. J Clin Oncol 19:3649-3659
27. Pagani A, Fischer-Colbrie R, Eder U, Pellin A, Llombart-Bosch A, Bussolati G (1995) Neural and mesenchymal differentiations in Ewing's sarcoma cell lines. Morphological, immunophenotypic, molecular biological and cytogenetic evidence. Int J Cancer 63:738-743
28. Yee D, Favoni RE, Lebovic GS, Lombana F, Powell DR, Reynolds CP, Rosen N (1990) Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest 86:1806-1814
29. Uslu R, Jewett A, Bonavida B (1996) Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis. Gynecol Oncol 62:282-291
30. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271-279
31. Erlacher M, Labi V, Manzl C, Bock G, Tzankov A, Hacker G, Michalak E, Strasser A, Villunger A (2006) Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J Exp Med 203:2939-2951
32. Hilger RA, Harstrick A, Eberhardt W, Oberhoff C, Skorzec M, Baumgart J, Seeber S, Scheulen ME (1998) Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol 42:99-104
33. Tanswell P, Heinzel G, Weisenberger H, Roth W (1995) Pharmacokinetic- pharmacodynamic and metabolite modeling with TopFit. Int J Clin Pharmacol Ther 33:550-554
34. Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, Bornhauser M, Ehninger G, Berdel WE, Baumgart J, Harstrick A, Bojko P, Wolf HH, Schindler AE, Seeber S (2000) Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 6:4209-4216
35. Fernandez HF, Tran HT, Albrecht F, Lennon S, Caldera H, Goodman MS (2002) Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 8:486-492
36. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182:1545-1556
37. Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM (1999) Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 274:5053-5060
38. Fichtner I, Becker M, Baumgart J (2003) Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Eur J Cancer 39:801-807
39. Bosanquet AG, Burlton AR (1994) Airborne cytotoxicity in the DiSC assay caused by solutions of treosulfan but not busulphan. Cytotechnology 16:131-136
40. Pauwels O, Atassi G, Kiss R (1995) Combination of computerized morphonuclear and multivariate analyses to characterize in vitro the antineoplastic effect of alkylating agents. J Pharmacol Toxicol Methods 33:35-45
41. Lavrik IN, Golks A, Krammer PH (2005) Caspases: pharmacological manipulation of cell death. J Clin Invest 115:2665-2672
42. Ploemacher RE, Johnson KW, Rombouts EJ, Etienne K, Westerhof GR, Baumgart J, White-Scharf ME, Down JD (2004) Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant 10:236-245
43. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, Juergens H (2006) Ewing's sarcoma family of tumors: current management. Oncologist 11:503-519
44. Paulussen M, Frohlich B, Jurgens H (2001) Ewing tumour: incidence, prognosis and treatment options. Paediatr Drugs 3:899-913
45. Boland I, Vassal G, Morizet J, Terrier-Lacombe MJ, Valteau-Couanet D, Kalifa C, Hartmann O, Gouyette A (1999) Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. Br J Cancer 79:787-792
46. Ashizuka S, Peranteau WH, Hayashi S, Flake AW (2006) Busulfan-conditioned bone marrow transplantation results in high-level allogeneic chimerism in mice made tolerant by in utero hematopoietic cell transplantation. Exp Hematol 34:359-368